Michael Singer

Michael Singer is a prominent figure in biotechnology and investment, currently serving as Chairman and Chief Strategy Officer on the Board of Directors at Cartesian Therapeutics, a clinical-stage biotech specializing in mRNA-engineered cell therapies. As Co-Founder and Chief Scientific Officer of Thirsty Brook Investments, a family investment firm aimed at backing innovative founders, Michael showcases expertise in identifying breakthrough technologies. Additionally, Michael holds roles as Entrepreneur-in-Residence at Yale University and on the Scientific Advisory Board for Yale School of Medicine. In governance, Michael contributes to various boards including Boston Cell Standards, Anodyne Nanotech, Pykus Therapeutics, and BioPorto Diagnostics. Previously, Michael co-founded Topokine Therapeutics, advancing adipocyte research before its acquisition by Allergan, and served as Clinical Faculty at Harvard Medical School. Michael holds a BS, MD, and PhD in Biology, Medicine, and Neuroscience from Yale University, alongside clinical training in Internal Medicine and Ophthalmology from Harvard Medical School.